Neurocrine Biosciences
NBIX
#1576
Rank
A$18.96 B
Marketcap
A$189.01
Share price
2.56%
Change (1 day)
2.64%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2025 (TTM): A$0.96 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are A$2.86 Billion. , an increase over its 2024 earnings that were of A$0.88 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2025

Annual earnings

Year Earnings Change
2025 A$0.91 B3.9%
2024 A$0.88 B96.41%
2023 A$0.44 B41.13%
2022 A$0.31 B73.74%
2021 A$0.18 B-8.82%
2020 A$0.20 B77.78%
2019 A$0.11 B49.83%
2018 A$75.48 M-142.57%
2017 -A$0.18 Billion-14.73%
2016 -A$0.21 Billion53.15%
2015 -A$0.14 Billion46.25%
2014 -A$92.85 Million29.66%
2013 -A$71.61 Million-3530.8%
2012 A$2.08 M-95.73%
2011 A$48.89 M
2009 -A$68.74 Million-45.38%
2008 -A$0.13 Billion-58.87%
2007 -A$0.31 Billion87.3%
2006 -A$0.17 Billion351.97%
2005 -A$36.14 Million-52.09%
2004 -A$75.44 Million-10.98%
2003 -A$84.74 Million
2001 -A$63.26 Million
1999 -A$28.53 Million108.32%
1998 -A$13.7 Million
1996 A$4.18 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
A$14.69 B 1,501.26%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$9.50 B 936.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$37.08 B 3,942.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$0.12 B-86.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-A$60.2 Million-106.56%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$72.86 M-92.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-A$6.92 Million-100.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.35 B 156.38%๐Ÿ‡ฌ๐Ÿ‡ง UK